🔥 POISE-3 Urology published in European Urology 🚨
In the largest randomized placebo-controlled #urology analysis of #TranexamicAcid (TXA), #TXA reduced major #bleeding risk by 37% (from 9.5% to 6.1%) with no clear increase in #thrombosis
More at https://t.co/Yypy7vb9Jz
#EBM
Treatment regret after MISTs for BPH — 15% of patients regret their choice.
155 patients (Aquablation, iTind, Rezum/WVTT, UroLift). Highest regret with PUL and WVTT. Prostate volume> 60 cc is associated with a 3-4× higher regret in those groups.
Patient selection and honest management of expectations matters
https://t.co/zXpLnDMhrE
🔬 55 studies, 25 years of data on ureteral stents in kidney transplantation — and "standard practice" looks very different depending on where you are.Infection risk, dwell time, removal techniques, selective use. Even the familiar deserves a second look.
https://t.co/lhk7NKxiLN
#WCET25 in sunny Phoenix, Arizona! Presented 3 abstracts and bumped into friends and collaborators from SG and around the world. Here's to more research from our group on the global stage in the future!
@steffiyuen@jteoh_hk@D_Castellani@DocGauhar@eejeanlim
@urogabe@LurieUrology@SocSurgErgo@SurgErgonomics I totally agree. Switched over a few months ago and really cant go back. Especially when its back to back cases. Unfortunately I had to invest in myself 😅
Happy to share our new study in @ProstateCPD about HOLEP! For men considering prostate surgery, it's about living better. Our new tool personalizes pre-op discussions to set accurate expectations & optimize recovery for improved QoL. #HoLEP
https://t.co/uyXJDASt2c
🚨 NEW in #EuropeanUrology By @saumyg@UrogerliMD@spsutkaMD@tbivala1@joanfundi et al
Can novel intravesical therapies change the game for non–muscle-invasive bladder cancer?
This systematic review explores:
✅ BCG-based combos
✅ Gene & immune therapies
✅ Innovative drug delivery
💡 Promising results, but long-term data still needed.
🔗 https://t.co/FdSKRfyUXF
#NMIBC #bladdercancer #urooncology
📢Publication alert!
Highlights:
1⃣Across 11 trials, TMT was associated with lower OS and CSS than RC
2⃣RC should remain the standard of care for nonmetastatic MIBC
3⃣TMT remains a valid alternative for carefully selected and informed patients
🔗https://t.co/EERejp5J6l
EAU 2025: Great catchup with friends and mentors from around the world. Honored to present our team's award-winning research on stage. Thank you to all of our co-authors, without which this would not have been possible! Looking forward to seeing everyone again soon :)
Happy to see our paper published !
🚨 MIBC is aggressive, and RC is the gold standard. But is TMT a viable alternative? Our meta-analysis evaluates survival outcomes using the highest-quality evidence to date. #BladderCancer#Oncology@fongkhiyung@vhlgan@KaeJackTay
Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis - European Urology Oncology https://t.co/svZ9owxpHL